---
document_datetime: 2024-05-03 13:49:54
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/scientific-conclusion/luxturna-h-c-psusa-00010742-202307-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf
document_name: luxturna-h-c-psusa-00010742-202307-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf
version: success
processing_time: 0.8055038
conversion_datetime: 2025-12-28 10:33:08.968878
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

22 February 2024 EMA/182154/2024 Committee for Medicinal Products for Human Use (CHMP)

## Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Active substance(s): voretigene neparvovec

Procedure No. EMEA/H/C/PSUSA/00010742/202307

Period covered by the PSUR:

24/07/2022 To: 23/07/2023

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Scientific conclusions

Taking into account the PRAC Assessment Report on the PSUR(s) for voretigene neparvovec, the scientific conclusions of PRAC are as follows:

In view of available data on chorioretinal atrophy, the PRAC concluded that the product information of products containing voretigene neparvovec should be amended accordingly.

Update of section 4.8 of the SmPC to add the adverse reaction 'chorioretinal atrophy' to the list of those related to voretigene neparvovec with a frequency 'not known', and additional details on chorioretinal atrophy in the Description of selected adverse reactions. The Package leaflet is updated accordingly.

Having reviewed the PRAC recommendation, the CHMP agrees with the PRAC overall conclusions and grounds for recommendation.

## Grounds for the variation to the terms of the Marketing Authorisation(s)

On the basis of the scientific conclusions for voretigene neparvovec the CHMP is of the opinion that the benefit-risk balance of the medicinal product(s) containing voretigene neparvovec is unchanged subject to the proposed changes to the product information

The CHMP recommends that the terms of the Marketing Authorisation(s) should be varied.